This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This AMACR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 323-351 amino acids from the C-terminal region of human AMACR.
SLC35G5
Reaktivität: Human
WB, ELISA
Wirt: Ziege
Polyclonal
unconjugated
Applikationshinweise
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
For FACS starting dilution is: 1:10~50
For IF starting dilution is: 1:10~50
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.5 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
AMAC1L2 (SLC35G5)
(Solute Carrier Family 35, Member G5 (SLC35G5))
AMAC antikoerper, AMAC1L2 antikoerper, solute carrier family 35 member G5 antikoerper, SLC35G5 antikoerper
Hintergrund
This gene encodes a racemase. The encoded enzyme interconverts pristanoyl-CoA and C27-bile acylCoAs between their (R)- and (S)-stereoisomers. The conversion to the (S)-stereoisomers is necessary for degradation of these substrates by peroxisomal beta-oxidation. Encoded proteins from this locus localize to both mitochondria and peroxisomes. Mutations in this gene may be associated with adult-onset sensorimotor neuropathy, pigmentary retinopathy, and adrenomyeloneuropathy due to defects in bile acid synthesis. Alternatively spliced transcript variants have been described.